Skip to main content

Mitomycin C/5-Fluorouracil Versus Cisplatin/5-Fluorouracil With Hyperfractionated Accelerated Radiotherapy in Locally Advanced Head and Neck Cancer: The ARO 04-01/AHMO Trial

In brief

Cisplatin did not improve 10-year survival over mitomycin in head and neck cancer

In a 364-patient trial, 10-year overall survival was 23% with cisplatin and 18% with mitomycin, with no significant survival advantage for either regimen. A competing-risk analysis found fewer distant metastases and progressions with cisplatin, but it also caused more kidney toxicity and adverse events; mitomycin remains an alternative for patients who cannot take cisplatin.

Journal
International journal of radiation oncology, biology, physics (Q1)
Published
17 November 2026
Study design
Non-randomized / quasi-experimental trial
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
V Budach, J Werner, M Wittlinger, R Fietkau, H Iro, R Engenhart-Cabillic, et al.
PMID
43044775
DOI
10.1016/j.ijrobp.2026.10.060

Why clinicians should know about it

Abstract

PURPOSE: Cisplatin-based concurrent chemoradiotherapy (CRT) is the standard for locally advanced head and neck squamous cell carcinoma (HNSCC). For cisplatin (CDDP)-ineligible patients, mitomycin C/5-fluorouracil (MMC/5-FU) is the most common alternative, but randomized comparisons are lacking. We compared MMC/5-FU with CDDP/5-FU as concurrent partners of hyperfractionated-accelerated radiotherapy (HART) in unresectable, locally advanced HNSCC. PATIENTS AND METHODS: In this multicenter phase III trial, 364 patients with stage IVA/IVB (UICC TNM 6th edition) oropharyngeal or hypopharyngeal HNSCC were randomized 1:1 to HART (72 Gy/6 weeks) plus either weekly CDDP 30 mg/m² (n=182) or MMC 10 mg/m² on days 5 and 36 (n=182), both with continuous-infusion 5-FU 600 mg/m²/d on days 1-5. The primary endpoint was overall survival (OS); secondary endpoints included freedom from progression (FFP), freedom from distant metastasis (FFDM), local, regional and locoregional control, and toxicity, analyzed by Kaplan-Meier and, post hoc, in a competing-risk framework. RESULTS: After a median follow-up of 87 months, CDDP/5-FU was not superior for OS (10-year OS 23% vs. 18%; hazard ratio [HR] 0.89, 95% CI 0.69-1.15; log-rank p=0.418). In the competing-risk analysis, CDDP/5-FU reduced distant metastasis (5-year cumulative incidence 25.9% vs. 36.1%; subdistribution HR 0.66, 95% CI 0.45-0.96; p=0.031) and progression (45.6% vs. 56.3%; subdistribution HR 0.73, 95% CI 0.55-0.98; p=0.037). Kaplan-Meier estimates were directionally consistent but not significant (10-year FFDM 66% vs. 52%; HR 0.69, 95% CI 0.48-1.02; p=0.060; FFP HR 0.79, 95% CI 0.59-1.05); local, regional and locoregional control (HR 0.80-1.01) and toxicity profiles did not differ. Serum creatinine (p<0.001) and the AE/SAE rate (24.2% vs. 15.4%; p=0.048) were higher with CDDP. CONCLUSION: ARO 04-01/AHMO did not show superiority of CDDP/5-FU over MMC/5-FU for overall survival. CDDP-based CRT remains the established standard for fit patients; MMC/5-FU is a safe and effective alternative with comparable overall survival and measurably lower nephrotoxicity and cumulative AE/SAE burden for CDDP-contraindicated patients. TRIAL REGISTRATION: DRKS00040575.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.